EGFR and non-small cell lung carcinoma: Finally, although the study may have included some patients who initiated 1L therapy as adjuvant therapy following LC-related surgery or radiation, the objective of the study was to present the unmet needs and economic burden among patients treated with EGFR-TKIs in real-world clinical practice, which includes patients who receive LC-related surgery or radiation prior to initiating 1L therapy with a treatment regimen for advanced NSCLC.